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Abstract 70 
Studies of chest computed tomography (CT) in patients with primary antibody deficiency 71 
syndromes (ADS) suggest a broad range of bronchial pathology. However, there are as yet no 72 
multicentre studies to assess the variety of bronchial pathology in this patient group. One of 73 
the underlying reasons is the lack of a consensus methodology, a prerequisite to jointly 74 
document chest CT findings. 75 
We aimed to establish an international platform for the evaluation of bronchial pathology as 76 
assessed by chest CT and to describe the range of bronchial pathologies in patients with 77 
antibody deficiency. 78 
15 immunodeficiency centres from 9 countries evaluated chest CT scans of patients with ADS 79 
using a predefined list of potential findings including an extent score for bronchiectasis. 80 
Data of 282 patients with ADS were collected. Patients with common variable 81 
immunodeficiency disorders (CVID) comprised the largest subgroup (232 patients, 82.3%). 82 
80% of CVID patients had radiological evidence of bronchial pathology including 83 
bronchiectasis in 61%, bronchial wall thickening in 44% and mucus plugging in 29%. 84 
Bronchiectasis was detected in 44% of CVID patients aged less than 20 years. Cough was a 85 
better predictor for bronchiectasis than spirometry values. Delay of diagnosis as well as 86 
duration of disease correlated positively with presence of bronchiectasis.  87 
The use of consensus diagnostic criteria and a pre-defined list of bronchial pathologies allows 88 
for comparison of chest CT data in multicentre studies. Our data suggest a high prevalence of 89 
bronchial pathology in CVID due to late diagnosis or duration of disease.  90 
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,QWURGXFWLRQ 93 
Primary antibody deficiency syndromes (ADS) are a heterogeneous group of immune 94 
disorders characterised by subnormal immunoglobulin levels and/or the inability to mount 95 
specific antibody responses (1). Common variable immunodeficiency disorders (CVID) are 96 
the most frequent humoral immunodeficiency requiring immunoglobulin replacement therapy 97 
with an incidence of approximately 1:25,000 ± 1:50,000 live births (2). 98 
Agammaglobulinaemia, XLA (x-linked agammaglobulinaemia) together with other variants, 99 
forms the second largest group affecting 3 to 6 per million live births (3). Recurrent bacterial 100 
infections of the respiratory tract are a major part of morbidity in both conditions although the 101 
frequency and severity are reduced by immunoglobulin replacement therapy (2,4-10). Airway 102 
infections are predominantly caused by encapsulated bacteria and can lead to persistent 103 
structural lung disease such as bronchiectasis (11,12). Presence of bronchiectasis is strongly 104 
associated with mortality in CVID and XLA (13,14). 105 
Early detection of the presence or progression of structural lung disease is essential to develop 106 
preventive or therapeutic strategies in this setting. Imaging techniques, in particular computed 107 
tomography (CT), are considered the gold standard for diagnosing structural lung disease 108 
(15,16).  109 
Chest X-ray (CXR) and pulmonary function tests (PFT) including spirometry, gas transfer and 110 
body plethysmography are readily available and can be repeated frequently, due to lower or 111 
absent dose of ionising radiation compared to sequential CT imaging. 112 
However, both methods lack sensitivity to detect structural lung disease in patients with 113 
antibody deficiency (11,17) or other conditions, such as cystic fibrosis (CF) (18).  114 
A sizeable body of literature reports bronchial morbidity in patients with antibody deficiency 115 
based on chest CT findings (17,19). However, these studies were almost exclusively single 116 
centre studies and are not easily comparable, since they used differing reporting systems and 117 
nomenclatures (11,20,21). The performance of multicentre studies therefore demands 118 
consensus data definition, reporting and scanning methodology to afford internal validity.  119 
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The difficulties of providing a standardised evaluation of chest CT scans in antibody 120 
deficiencies may have contributed to the apparent paucity of clinical studies describing 121 
preventive or therapeutic interventions in this patient group (22). 122 
The present study is the result of an international multicentre and multidisciplinary 123 
collaboration aiming to create a common platform of chest CT findings from patients with 124 
primary antibody deficiencies. Based on a large number of chest CT studies, the distribution, 125 
variety and extent of pulmonary pathology was assessed. Herein, we report the findings on 126 
bronchial pathology in conjunction with clinical data and pulmonary function testing. Based 127 
on these findings, we propose a method to document bronchial pathologies for multicentre use 128 
such as patient registries. 129 
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0HWKRGV 130 
Development of a consensus list of CT findings 131 
In the Chest CT in Antibody Deficiency Group, immunologists, radiologists and 132 
pulmonologists agreed a list of chest CT findings with the aim of collecting pathologies of 133 
potential relevance for patients with PAD. The list was based upon clinical experience and 134 
review of the literature. In order to use radiological terminology that is both widely accepted 135 
and defined by an image repository, the syllabus of the Fleischner Society (15) was used. A 136 
short form of definitions and exemplary images was provided to the participating centres 137 
(http://www.chest-ct-group.eu/imagerepository). 138 
The Chest CT Group criteria scored 16 items (table 1, online repository), including 4 on 139 
bronchial pathologies. Bronchial wall thickening was defined as a diameter of a bronchial 140 
wall being larger than one third of the outer diameter of the accompanying bronchial artery, of 141 
more than a fifth of the outer diameter of the bronchus. Bronchiectasis was defined as an 142 
airway lumen larger in diameter than the outer diameter of the accompanying bronchial 143 
artery. Two items were scored only as present or absent (bronchial wall thickening, 144 
atelectasis). Mucus plugging was additionally scored for the distribution pattern (central or 145 
peripheral). Bronchiectasis was scored for distribution and extent, the latter comprising a 146 
VLPSOLILHGEURQFKLHFWDVLVVFRUHRUOREHVDIIHFWHGRUF\VWLFFKDQJHVLQOREHV 147 
 148 
Chest CT scans and data collection  149 
Chest CT scans were performed according to local guidelines of the participating centres and 150 
evaluated locally. All chest CTs were acquired at full inspiratory capacity by using a thin slice 151 
protocol of acquisition.  152 
The diagnosis of the immunodeficiency was based on the diagnostic criteria of the European 153 
Society for Immunodeficiencies (ESID)(23). Only CT scans that were performed in patients 154 
with a stable clinical condition were included. The radiologists were requested to employ 155 
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chest CT scoring system provided by the Chest CT in Antibody Deficiency Group in addition 156 
to their local practice.  157 
CT findings along with clinical data were documented with the ESID online registry (24). 158 
Some centres preferred to send the data with an anonymised chest CT documentation sheet 159 
(table I, online repository) to the study centre. All data were stored in a database in an 160 
anonymised fashion. 161 
 162 
Clinical data collection 163 
Similarly, clinical data were collected with a second documentation sheet with items identical 164 
to the ESID registry (table II, Clinical Data Sheet in the online repository). The clinical data 165 
sheet comprised data on lung function (spirometry, body plethysmography and carbon 166 
monoxide diffusion capacity), pattern of cough and use of antibiotics). 167 
Since lung function data were only available DV³SHUFHQWDJHRISUHGLFWHGIRUKHLJKWDQG168 
ZHLJWK´ in several centres, data were collected accordingly (not as absolute measurements). 169 
Cough lasting longer than 8 weeks was defined as chronic cough (25). Duration of disease 170 
was calculated as time interval from date of onset of disease specific symptoms to date of CT 171 
scan. 7KHLQWHUYDOIURPGDWHRIGLDJQRVLVWR&7VFDQZDVFRQVLGHUHG³GXUDWLRQRIWKHUDS\´ 172 
based on the assumption that a diagnosis of CVID or XLA is generally followed by a rapid 173 
initiation of immunoglobulin replacement therapy. ³Delay of diagnosis´ was the time from 174 
onset of symptoms to diagnosis. 175 
 176 
Quality assurance, data processing and statistical analysis 177 
Written informed consent was obtained for documentation within the ESID Registry (2). Data 178 
were transferred into a relational database (Microsoft Access V2010 Microsoft, Redmont, 179 
WA (USA)) and evaluated anonymously. The inter-rater reliability of the CT findings as 180 
documented in the chest CT pathology form was assessed by calculation of the intra-class 181 
correlation coefficient (ICC) between independent radiologists. Descriptive data were 182 
calculated as mean and standard deviation, or, if appropriate, as median and interquartile 183 
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range. Categorical data were reported as frequencies and percentages. Groups were compared 184 
using the t-test unless the data were not normally distributed. In this case, the following 185 
nonparametric methods were used. Categorical variables were analysed with Chi-Square tests. 186 
&RUUHODWLRQVZHUHFDOFXODWHGDV3HDUVRQ¶VFRHIILFLHQWDQGZLWKOLQHDUUHJUHVVLRQDQDO\VLV187 
Explanation of variance was calculated using linear regression analysis. Dependence of 188 
variables on parametric data was assessed by logistic regression analysis. The influence of 189 
several variables was assessed by conditional forward and backward logistic and linear 190 
regression analysis. A p-value < 0.05 was considered statistically significant. Differences in 191 
prevalence of parameters between sexes were calculated by Mann Whitney U Test. All 192 
statistical analyses were performed with the Statistical Software Package for the Social 193 
Sciences (SPSS; V 24, IBM, Armonk, New York (USA)). 194 
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5HVXOWV 195 
Study Population 196 
15 centres in 9 countries contributed chest CT findings of 282 patients (table III in online 197 
repository). Clinical data were available in 192 patients. Diagnoses were CVID (232 patients 198 
(82%)), XLA (28 patients (10%)), and other PAD (22 patients (8%). Data of the latter group 199 
are not included in this manuscript due to their lack of homogeneity.  200 
Baseline characteristics of the CVID and XLA patient cohorts and data on clinical history are 201 
given in table 1. For age distribution see figure I in the online repository.  202 
 203 
Quality assurance and data quality 204 
The CT pathology documentation form was assessed for inter-rater reliability based on 205 
assessment by 4 radiologists of 21 randomly chosen CT studies. Rating was in good or very 206 
good agreement, as shown by intra-class correlation coefficients (ICC) (Calder et al. 207 
Paediatric Radiology 2014 44:1496±1506), ICC was 0.79 (p < 0.001) for atelectasis, 0.957 (p 208 
< 0.001) for mucus plugging, and 0.917 (p < 0.001) for bronchiectasis severity. Rating of 209 
bronchial wall thickening, however, was not reliable (ICC 0.332, p = n.s.). 210 
In the main study, rating on the 4 items on bronchial pathologies was given in 94.9% (SD 211 
2.1%) of the CT scans. The highest rate of missing data was present in the item termed 212 
³mucus plugging´Zith missing data in 7.8 % of the cases. Anthropometric data were 213 
available from 64%, spirometry from 62%, cough frequency from 64%, antibiotic treatment 214 
regimen from 72%, and body plethysmography from 28% of the patients. 215 
 216 
Bronchial pathology in CVID 217 
80% of the CVID patients had radiological evidence of some form of bronchial pathology. 218 
Bronchiectasis had the highest prevalence of all bronchial pathologies and was reported in 219 
61% of the CVID cohort, followed by bronchial wall thickening (44%), atelectasis (32 %), 220 
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and mucus plugging (29%). Mucus plugging was more frequent in the periphery (20%) than 221 
in a distributed pattern (central and peripheral, 9%, figure 1). The prevalence of bronchial 222 
pathologies did not differ between sexes. Bronchiectasis was not associated with other 223 
bronchial pathology. Of the patients with bronchiectasis, 64% had no evidence of mucus 224 
plugging, 60% had no atelectasis, and 43% had no evidence of bronchial wall thickening. 225 
 226 
Impact of age and duration of disease on bronchial pathology in CVID 227 
The prevalence of bronchiectasis was lowest in the patient group undergoing CT at < 20 years 228 
at 44% and increased steadily with age to 79% in the age group \HDUVILJXUH$Extent 229 
of bronchiectasis showed an age related increase (R2 =0.029; F=6.6; p=0.01, figure 2 B-D). 230 
3DWLHQWV\HDUVKDGWKHKLJKHVWSURSRUWLRQRIextensive disease (3 or more lobes affected 231 
and/or cystic changes) with 36% of this age group affected (figure 2D).  232 
In contrast to bronchiectasis, prevalence of bronchial wall thickening, atelectasis and mucus 233 
plugging did not rise with age nor with duration of disease or of therapy. Bronchiectasis was 234 
associated with bronchial wall thickening, atelectasis and mucus plugging only in younger age 235 
groups (table IV in online repository). 236 
In multiple regression analysis, duration of the disease was a predictor for the presence and 237 
extent of bronchiectasis, but age, sex and duration of therapy were not. Each year of disease 238 
was associated with an additional risk of bronchiectasis by 4.4% (p = 0.07) and an increase of 239 
the severity score by 0.025 (p<0.001) (Figure IV, online repository).  240 
Patients with a longer delay of diagnosis had a higher extent of bronchiectasis, although this 241 
association was comparatively weak (F = 6.14, p = 0.015 in analysis of variance, figure 5). 242 
Patients with advanced bronchiectasis tended to have higher trough IgG levels (rpearson= 0.19, 243 
p = 0.048).  244 
 245 
Bronchial Pathology in XLA 246 
The prevalences of bronchiectasis, atelectasis and mucus plugging, but not of bronchial wall 247 
thickening, were higher in the XLA cohort as compared to the CVID cohort (Fig. 1a+b). The 248 
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extent of bronchiectasis was also more strongly related to age (rPearson = 0.6, p < 0.001, Figure 249 
II in online repository) and to duration of disease (rPearson = 0.7, p < 0.001) than in CVID 250 
patients. Again, duration of therapy correlated less strongly than age or duration of disease 251 
with the extent of bronchiectasis in XLA patients, but more so than in CVID patients (rPearson 252 
= 0.55, p = 0.017). Bronchiectasis was also associated with bronchial wall thickening (rPearson 253 
= 0.44, p = 0.018), but not to mucus plugging or atelectasis in this cohort.  254 
 255 
Lung function 256 
CVID patients showed mild obstructive lung disease in the older age groups without 257 
restriction, FEV1 was 87.8 (19.6) % predicted in patients < 20 years and FEV1 (FEV1, figure 258 
$SUHGLFWHGLQSDWLHQWV\HDUV7KHUHZDVDVLPLODUDJHGHSHQGHQWGHFOLQH259 
in maximal expiratory flow at 25% of vital capacity (MEF25), and total lung capacity (TLC), 260 
but not of vital capacity (VC). However, explanation of variance of all parameters by age was 261 
weak (FEV1: R2 = 0.041, p = 0.016, F = 5.994; MEF25: R2 = 0.053, p = 0.01, F = 6.882; TLC: 262 
R2 = 0.072, p = 0.028, F = 5.061). In XLA patients, advance of lung disease with age was 263 
more obvious. FEV1 declined from 95.7 (8.7) % predicted in patients aged less than 20 years 264 
WRSUHGLFWHGLQSDWLHQWV\HDUV$FFRUGLQJO\OLQHDUUHJUHVVLRQDQDO\VLV265 
showed a stronger relation between age and decline in lung function parameters in XLA 266 
patients (vital capacity (VC): R2 = 0.351, p = 0.005, F = 10.285; FEV1: R2 = 0.529, p < 0.001, 267 
F = 22.439; MEF25: R2 = 0.637, p = 0.002, F = 17.511; TLC: R2 = 0.072, p = 0.028, F = 268 
5.061).  269 
CT findings and lung function 270 
Presence of bronchial wall thickening, bronchiectasis or mucus plugging was associated with 271 
a lower FEV1 in CVID patients (table V online repository, figure 3B). The combination of 272 
bronchiectasis and bronchial wall thickening showed a further decline (n = 54, FEV1 of 69.3 273 
(23.3) % % predicted). Patients with a severe lung disease as indicated by spirometry (FEV1 < 274 
40 % predicted) had a high prevalence of bronchiectasis (89%). However, normal FEV1 (> 80 275 
% predicted) did not preclude the presence of bronchiectasis . 59% of the patients with a 276 
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normal lung function had bronchiectasis (figure 3). Thus, spirometry was a poor predictor for 277 
presence (sensitivity: 48.9%) or absence of bronchiectasis (specificity: 68.8%, table IV online 278 
repository). Findings of bodyplethysmography and carbon monoxide diffusion capacity were 279 
not better associated with structural bronchial pathology. 280 
 281 
Cough 282 
The majority of CVID patients for whom clinical data were available (n = 147) had 283 
occasional (53.1%), or recurrent or chronic cough (34.7%). Prevalence of chronic cough 284 
increased with age and rose from 18% in the age group < 20 years to 38.5% in the age group 285 
\HDUVR2 = 0.054, F = 8.315, p = 0.005). Quality of cough also changed with age; a 286 
higher proportion of patients had productive cough and frequency of cough with increasing 287 
age (79% in age group  60 years). In this age group all patient suffered from cough (fig. 4). 288 
Of the patients who coughed chronically, 75% had evidence of bronchiectasis. Nevertheless, 289 
60% of the subjects with occasional cough also had bronchiectasis. Almost all patients with 290 
radiological evidence of bronchiectasis had some sort of cough (92.7%). These patients were 291 
twice as much likely to have productive rather than unproductive cough (66.7 vs. 33.3%). 292 
Patients with bronchiectasis and productive cough had a more compromised lung function test 293 
(mean FEV1 = 71.9 (26.1) % predicted) than those with bronchiectasis and unproductive 294 
cough (mean FEV1 = 86.2 (25.0) % [pred.], p = 0.033).  295 
 296 
Use of antibiotics  297 
Use of antibiotics  varied considerably. Intermittent antibiotic therapy was more frequent 298 
(47.7%) than maintenance (26.8%) therapy in n = 163 CVID patients, for whom data were 299 
available. Usage varied also for patients with chronic cough (n = 51): intermittent 51.8% and 300 
maintenance 40.8% therapy and for patients with bronchiectasis (n = 95): intermittent 44.2%, 301 
and maintenance therapy 33.7%. Courses of antibiotic therapy were used more commonly as 302 
the proportion of patients with bronchiectasis rose: 51.2% of the patients who received no 303 
antibiotic therapy (n = 42) had bronchiectasis, 59.2% of the patients with intermittent therapy 304 
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(n = 71) had bronchiectasis, and 72.7% of the patients with mainentance antibiotic therapy (n 305 
= 44) had bronchiectasis. Our data did not discriminate between prophylactic and therapeutic 306 
use of antibiotics.  307 
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Discussion 308 
The purpose of this study was to identify the range and extent of bronchial pathology as 309 
detected by chest CT in antibody deficient patients. A multicentre approach was used, as 310 
antibody deficiencies are a relatively rare condition. CT findings provide primarily qualitative 311 
data, which makes multicentre studies difficult to accomplish in the absence of pre-agreed 312 
criteria. With the Chest CT in Antibody Deficiency Group, we set up a catalogue of 313 
pathologies that were reported in the literature or seen in our own patients. In order to compile 314 
data that is comparable, we agreed upon common radiological terminology, set up an image 315 
repository, and agreed upon common definitions.  316 
We found a high overall prevalence of bronchial pathology, with bronchial wall thickening 317 
and bronchiectasis present in 52% and 61% of the CVID patients, respectively. The present 318 
study is the first multicentre study to also assess extent of bronchiectasis in children and 319 
adults with antibody deficiency. While the prevalence of bronchiectasis increased with age, it 320 
was already present in our youngest age group (< 20 years) at 43%. Duration of disease, 321 
however, was the best predictor for presence and extent of bronchiectasis, with age and sex 322 
having no additional impact. Importantly, also delay of diagnosis correlated significantly with 323 
the extent of bronchiectasis. Atelectasis and mucus plugging were reported less frequently, 324 
but also at sizeable proportions of the patients.  325 
As expected, the prevalence of bronchiectasis increased with age which did not apply to the 326 
bronchial wall thickening, atelectasis and mucus plugging. While bronchiectasis correlated to 327 
the other pathologies at younger age groups (table 4, online repository), in the older age 328 
groups bronchiectasis appeared to be more the accumulation of damage acquired in past and 329 
present inflammatory processes. Age as well as duration of disease accounted for more of the 330 
variation in bronchiectasis and lung function in XLA than in CVID. This may reflect the 331 
earlier and more homogeneous onset of immunodeficiency in XLA (8) compared with the 332 
predominantly adult onset of CVID (11), although differences in the pathogenesis of lung 333 
disease cannot be excluded. 334 
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Similar to prevalence and extent of bronchiectasis, spirometry values tended to be more 335 
pathological at higher age groups. Along with bronchiectasis, prevalence of chronic and 336 
productive cough increased with age, reaching 100%, in the oldest age group (> 60 years). 337 
Cough frequency correlated better to bronchiectasis than spirometry. XLA patients had more 338 
advanced bronchial disease in the older age groups when compared to the CVID cohort. This 339 
is consistent with data from an Italian cohort (26) who had a cumulative risk of developing 340 
structural lung disease of 92% by the age of 25 years, which was higher than in the Italian 341 
CVID cohort that had a prevalence of bronchiectasis of 54% at an average age of 41 years 342 
(27). 343 
Our data show a rate of bronchiectasis in CVID patients (61%) in the same range as reported 344 
with the as yet largest CVID cohort of Italian patients (54%) (27). In smaller chest CT studies, 345 
bronchiectasis rates varied between 29 and 78% (summarised in (17)). A meta-analysis of 346 
other studies summarised data from 587 CVID patients published in 26 studies. The authors 347 
reported an overall prevalence of 73% of pulmonary pathologies, mainly bronchiectasis and 348 
bronchial wall thickening.  349 
The present study has several limitations: 350 
First, it was not designed as a cross-sectional cohort study to assess the prevalence of 351 
particular pathologies. The participating centres varied in their policies to perform chest CT 352 
between clinical grounds and routine use. Since some centres performed chest CTs only on 353 
clinical grounds, the study is likely to overestimate prevalence and extent. The relatively high 354 
prevalence of bronchiectasis in children and adolescents (43% in the age group < 20 years) 355 
may be partly explained by the fact, that the majority of the CT studies in this age group was 356 
performed in a centre that performed CT on clinical grounds. 357 
Second, we employed no training or quality control measures for our raters. Although we 358 
used an internationally accepted vocabulary (15), published an image repository on our 359 
website, we cannot be sure that all raters shared similar levels of expertise. Appreciating this, 360 
we designed the list of CT findings of this study to be as simple as possible, indicating merely 361 
presence or absence for most pathologies. A study on inter-rater reliability with our list of CT 362 
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findings showed very high rates of inter-rater agreement for all findings, in particular for the 363 
bronchiectasis score. Rating of bronchial wall thickening, however, was unreliable which is 364 
well recognized in the literature (28). 365 
Despite these limitations, our data may nevertheless be meaningful. Our CVID study cohort 366 
has an age and sex distribution that is close to the distribution of the ESID registry. Also, the 367 
size of the compiled cohort is larger than previous reports in the literature.  368 
Bronchiectasis is the finding most frequently reported in previous studies. Our data on the 369 
prevalence of bronchiectasis (61%) are in the same range compared to the as yet largest CVID 370 
cohort study (54%) (27). The latter study is likely to give the most accurate estimate on 371 
prevalence of bronchiectasis for it was based on regular chest CT scans. Other studies based 372 
on smaller cohorts reported bronchiectasis rates between 29 and 78% (summarised in (17)).   373 
Chest CT scans identified a high proportion of respiratory pathology which did not appear to 374 
be identified by symptoms or lung function. This applied in particular to patients with low 375 
grade bronchiectasis in which spirometry tended to be normal (figure III in online repository). 376 
Also, the decline in FEV1 with age was relatively small in our cohort, compared to other 377 
conditions with chronic lung disease, such as primary ciliary dyskinesia (PCD) (29,30). 378 
However, spirometry appeared to better discriminate between prevalence or absence of 379 
bronchiectasis in our patient group than reported in PCD or CF (31,32). While a sensitivity of 380 
49% and a specificity of 68.8% for detection and exclusion of bronchiectasis are far from 381 
satisfactory, the use of spirometry in routine management in patients with ADS may be at 382 
least as adviseable as in PCD or CF. Although spirometry may not detect mild bronchiectasis, 383 
it is likely to be a meaningful parameter for advanced stage of bronchial disease. In addition, 384 
any decline in spirometry in a given patient, even within the normal range, may indicate 385 
progressing lung damage and hence should prompt further evaluation. The higher 386 
susceptibility to irradiation damage in some subgroups of CVID also supports the notion to 387 
regularly monitor pulmonary disease without use of ionising radiation. Particular attention 388 
should be paid to children and adolescents. Although bronchiectasis may be overestimated in 389 
this age group, the true prevalence of bronchiectasis is likely to be high enough to warrant 390 
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high priority for prevention of development of structural lung disease. Spirometry needs to be 391 
complemented by more sensitive functional tests. The multiple breath washout technique may 392 
be particularly promising for detecting bronchiectasis, as shown in CF and other conditions 393 
(31). 394 
One important finding of this study is the observation that patients with a delay of diagnosis 395 
correlated with advanced formation of bronchiectasis in CVID. This finding argues that 396 
awareness of primary immunodeficiencies and early diagnosis may be particularly beneficial.  397 
Prevalence and extent of bronchiectasis also increased with the years of disease, suggesting a 398 
repeated or continuous burden of bronchial inflammation throughout the course of disease.  399 
Cough turned out to be more closely related to bronchial disease than parameters of 400 
spirometry. Again, patient selection may have biased this surprisingly high proportion of 401 
patients with clinical evidence of lung disease. However, cough and other clinical parameters, 402 
e.g. sputum volume, colour, frequency of chest exacerbations, or frequency of antibiotic 403 
therapy, may be valuable tools in future interventional trials. Our findings also argue that we 404 
do need better monitoring strategies for development of pulmonary pathologies before chronic 405 
or productive cough develops.  406 
Therapeutic regimens for antibiotic treatment of CVID patients with bronchiectasis, 407 
pathologic spirometry or productive cough differ substantially in the present study as in others 408 
(9,11). Chapel et al. found no clear evidence that bronchiectasis can be prevented by 409 
prophylactic maintenance antibiotic therapy. Bondioni et al. recommended early detection of 410 
pulmonary changes to adjust antibiotic therapy (21,33,34). 411 
Evidence for the benefit of antibiotic therapy or other interventions to prevent or ameliorate 412 
progress of bronchiectatic lung disease in other conditions is conflicting. Among the reasons 413 
for the lack of efficacy trials in immunodeficiency is the difficult choice of outcome 414 
parameters. FEV1 and other lung function parameters show relatively little changes over time 415 
rendering them less sensitive than desirable. Magnetic resonance imaging (MRI) has made 416 
substantial progress in the detection of pulmonary pathology but is less widely available (35). 417 
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Chest CT is still considered the gold standard for detection of structural bronchial pathology 418 
(17) and sensitive for changes over time (21).  419 
Our bronchiectasis score was designed for use in routine care without prior training of the 420 
raters. This score is clearly too crude to specifically assess progress of bronchiectasis. More 421 
detailed extent scores for bronchiectasis in CVID were applied in 2 single centre studies 422 
(20,21,36), demonstrating that progress of lung disease is detectable by chest CT at intervals 423 
as short as 5 years.  424 
Given the size and the relevance of pulmonary morbidity in primary antibody deficiencies, the 425 
present study argues to optimise the use of chest CT. First, there is a need for a detailed score 426 
on bronchial and other pulmonary pathologies for interventional trials (37). Second, chest CT 427 
scans which are performed as part of routine care in primary antibody deficiencies should be 428 
documented in a uniform manner in a patient registry along other clinical and immunological 429 
data. Documentation should provide more quantitative data than the one used in the present 430 
study, but still be compatible with routine care. The Chest CT Group has elaborated a 431 
proposal for severity graded documentation of bronchial pathology (table VI, online 432 
repository). Since this will be more prone to variation between different raters, we plan to 433 
implement quality control measures that include rating of test images.  434 
In summary, chest CT is a highly sensitive method for assessment of structural abnormalities 435 
of the bronchial airways. If it is complemented by lung function and clinical parameters, it can 436 
provide essential information on the progress and nature of lung disease in patients with 437 
antibody deficiencies. However, rating of CT findings for cohorts requires a consensus as to 438 
how the findings are documented. The present study shows how a multidisciplinary and 439 
multicentre approach can come into operation and affords a rationale how to shape future 440 
steps towards a better management of lung disease in antibody deficiency.   441 
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7DEOHV 562 
Table 1 563 
Table 1: Characteristics of the study population, sorted by the two main diagnosis groups.  564 
 565 
 CVID XLA 
n 232 28 
Female, n 113 (49%) 0 
Age, mean (SD; range) [years] 36.6 (17.6; 1.6-79.3) 25.1 (15.7, 4.0-53.1) 
Children and adolescents < 18 years, n 46 (20%) 16 (53%) 
Duration of disease, mean (SD; range) 
[years] 
17.3 (13.5) 15.6 (11.6) 
Delay of diagnosis, mean (SD; range) [years] 6.5 (8.3; 0 ± 48.8) 2.8 (4.7; 0 ± 17.3) 
Duration of therapy, mean (SD; range) 
[years] 
10.8 (9.8; 0 ± 42.0) 11.3 (7.8; 0.9 ± 29.7) 
IgG trough levels, mean (SD) [g/L] 7.0 (3.0) 7.9 (2.1) 
 566 
Abbreviations: CVID: common variable immunodeficiency disorders, XLA: X-linked 567 
agammaglobulinaemia; SD: standard deviation 568 
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Figure 1 570 
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Fig.1.: Prevalence of bronchial pathology in patients with CVID (A) and XLA (B). 572 
573 
28 
 
Figure 2 574 
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Fig.2: Prevalence, extent and age distribution of bronchiectasis in 232 CVID patients. 576 
A: Global prevalence (any bronchiectasis), B: 1 lobe affected, C: 2 or 3 lobes affected, and D: 577 
4 or more lobes affected or cystic changes. Lingula counted as a separate lobe. The extent 578 
score correlated significantly with age (rPearson = 0.171, p = 0.01). 579 
580 
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Figure 3 581 
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 Fig. 3. A: Mean (SD) forced expiratory volume in 1 second as percentage of predicted 583 
value (FEV1 % [pred.]) in 232 CVID patients stratified in age groups. FEV1 % predicted 584 
declined significantly with age (rPearson = -0.203, p = 0.016). B: Prevalence of bronchiectasis 585 
stratified by age groups. Prevalence and extent of bronchiectasis increased with deteriorating 586 
FEV1 (rPearson = -.22, p = 0.009 and (rPearson = -.322, p < 0.001 for prevalence and extent of 587 
bronchiectasis with FEV1 % predicted. 588 
589 
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Figure 4 590 
 591 
Fig.4. Prevalence of productive and unproductive cough of 120 CVID patients stratified 592 
in age groups. Productive cough was more frequent with age (rPearson = 0.222, p = 0.012).  593 
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Figure 5 595 
 596 
 597 
 598 
 599 
Fig.5: Severity of bronchiectasis in relation to duration of disease, duration of medical 600 
DWWHQWLRQ IROORZLQJ GLDJQRVLV RI &9,' ³GXUDWLRQ RI WKHUDS\´ DQG GHOD\ RI GLDJQRVLV601 
Boxplots indicate median and interquartiles, whiskers range. Open dots show outliers. Delay 602 
of diagnosis correlates significantly with severity of bronchiectasis (p=0.03) 603 
 604 
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Table I 606 
Documentation sheet for chest CT findings, section bronchial pathology. 607 
 608 
609 
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Table II 610 
Clinical data sheet611 
 612 
613 
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Table III 614 
 615 
616 
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Table IV  617 
Age dependent correlation of bronchiectasis with other bronchial pathology in 232 618 
CVID patients. 619 
  Bronchiectasis correlates with 
  
Bronchial Wall Thickening 
(n=103) Atelectasis (n=74) Mucus Plugging (n=67) 
Age Group rPearson p rPearson p rPearson p 
< 20 0.325 0.029 0.337 0.020 0.421 0.007 
20 - < 40  0.595 < 0.001 0.283 0.019 0.447 <0.001 
40 - < 60 0.309 0.006  n.s.  n.s. 
   n.s.  n.s.  n.s. 
All Age 
Groups 0.363 < 0.001 0.250 < 0.001 0.322 < 0.001 
620 
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Table V 621 
Contigency table of lung function and bronchiectasis. A FEV1 < 80 % predicted is 622 
considered as pathological. Presence or absence of bronchiectasis as defined by chest CT. 623 
Sensitivity of FEV1 <80% % predicted to assess all cases of bronchiectasis 0.489 
Specificity of FEV1 >80% % predicted for no bronchiectasis 0.688 
Positive predictive value 0.750 
False negative rate (miss rate) 0.511 
False positive rate (fallout) 0.313 
Negative predictive value 0.413 
 624 
625 
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Table VI 626 
Revised score for bronchial pathologies of the Chest CT in ADS group. For definitions of 627 
the various items see www.chest-ct-group.eu. 628 
Bronchial Pathology 
Airway wall thickening 
 
      
Number of lobes affected 
(lingula counts as a lobe) 
b c d e f g h 
Most severely affected bronchia: Extent as in % of accompanying vessel 
 < 33% 33-66% >66% 
Bronchiectasis 
 
      
Number of lobes affected b c d e f g h 
Most severely affected bronchia: Extent as in % of accompanying vessel 
 < 33% 33-66% >66% 
Mucus plugging (large airways) 
Number of lobes affected b c d e f g h 
Mucus plugging (small airways ± tree in bud) 
Number of lobes affected b c d e f g h 
Atelectasis (volume loss > 50%) 
Number of lobes affected b c d e f g h 
 629 
630 
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Figure I 631 
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Fig. I: Age distribution of the cohort with CVID (A) and XLA (B) 633 
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Figure II 635 
 636 
Fig. II: Prevalence of bronchiectasis in 28 patients with XLA. 637 
638 
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Figure III 639 
 640 
 641 
Fig. III. Individual levels of FEV1 % predicted of 143 CVID patients in relation to extent 642 
of bronchiectasis. Upper right box: patients with bronchiectasis with normal lung function 643 
(FEV1>80% % predicted: 47 (58.8%) out of the 80 patients with normal lung function. Lower 644 
left box: patients with no bronchiectasis, but with abnormal lung function (FEV1<80% % 645 
predicted): 15 (25%) out of 60. The correlation between the extent score of bronchiectasis and 646 
FEV1 was significant, but weak, in linear regression analysis (F = 15.9, R2 = 0.10, p < 0.001). 647 
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Fig. IV: Correlation of prevalence of bronchiectasis with duration of disease. The 648 
cumulative prevalence of bronchiectasis in relation to the duration of disease. 1 year of 649 
disease is associated with an average increase of risk of bronchiectasis by 4.8% (p = 0.015). 650 
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